Weight change in people with type 2 diabetes: Secular trends and the impact of alternative antihyperglycaemic drugs

Diabetes, Obesity and Metabolism

Volumn 14, Issue 5, 2012, Pages 424-432

  Morgan, C Ll ^a   Jenkins Jones, S ^a   Evans, M ^b   Barnett, A H ^c   Poole, C D ^a   Currie, C J ^d  

^a Pharmatelligence ^*  (United Kingdom)

^b LLANDOUGH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antidiabetic drugs; Obesity; Secular trends; Type 2 diabetes; Weight change

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXENDIN 4; INSULIN; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; SIDE EFFECT; UNITED KINGDOM; WEIGHT CHANGE; WEIGHT GAIN;

EID: 84859442090     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01552.x     Document Type: Article

References (25)

1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 1998; 317: 703-713.
2. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009; 32: 1-11.
3. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
4. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010; 33: 501-506.
5. Eberhardt MS, Ogden C, Engelgau M, Cadwell B, Hedley AA, Saydah SH. Prevalence of overweight and obesity among adults with diagnosed diabetes-United States, 1988-1994 and 1999-2002. Morb Mortal Wkly Rep 2004; 53: 1066-1068.
6. Howel D. Trends in the prevalence of obesity and overweight in English adults by age and birth cohort, 1991-2006. Public Health Nutr 2010; 26: 1-7.
7. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
8. Guisasola FÁ, Povedano ST, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008; 10: S25-S32.
9. McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab 2010; 12: 431-436.
10. Heller S. Weight gain during insulin therapy in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2004; 65: S23-S27.
11. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002; 25: 330-336.
12. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
13. Druckier DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
14. Gilbert MP, Pratley RE. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. Am J Med 2009; 122(Suppl. 6): S11-S12.
15. GPRD Division of the Medicines and Healthcare Products Regulatory Agency. The General Practice Research Database. Available from URL:. Accessed 15 September 2011.
16. The NHS Information Centre. Health Survey for England 2008 Trend Tables. Available from URL:. Accessed 12 September 2011.
17. Morgan CL, Peters JR, Currie CJ. The changing prevalence of diagnosed diabetes and its associated vascular complications in a large region of the UK. Diabetic Medicine 2010; 27: 673-678.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25: S5-S20.
19. Rowe R, Cowx M, Poole C, McEwan P, Morgan C, Walker M. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss. Curr Med Res Opin 2005; 21: 1885-1890.
20. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13, 000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 1422-1426.
21. Lutgers HL, Gerrits EG, Sluiter WJ et al. Life expectancy in a large cohort of type 2 diabetes patients treated in primary care (ZODIAC-10). PLoS One 2009; 4: e6817.
22. Roland M. Linking physicians' pay to the quality of care-a major experiment in the United Kingdom. N Engl J Med 2004; 351: 1448-1454.
23. Currie CJ, Peters JR, Evans M. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008. Diabet Med 2010; 27: 744-752.
24. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140-1147.
25. Currie CJ, Peters JR, Tynan A et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481-499.